Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Regulatory News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

Share Price is delayed by 15 minutes
Get Live Data
41.00    -0.10 (-0.24%)
Bid:
40.00
Ask:
42.00
Spread: 2.00 (5.00%)
Market Cap: £83.99m
FARN Live PriceLast checked at - London Stock Exchange

Intraday Faron Pharmaceuticals Share Chart

Holding(s) in Company

10 May 2021 14:30

RNS Number : 1199Y
Faron Pharmaceuticals Oy
10 May 2021
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Faron Pharmaceuticals Ltd

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

x

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii: (Decrease of holding due to issuance of new shares)

3. Details of person subject to the notification obligationiv

Name

Timo Syrjälä

 

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

 7.5.2021

6. Date on which issuer notified (DD/MM/YYYY):

10.5.2021

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

 14.09%

14.09%

 50,457,874

Position of previous notification (if

applicable)

13.57%

13.57%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

FI4000153309

2,561,402

4,550,285

5.08%

9.02%

SUBTOTAL 8. A

7,111,687

14.09%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Timo Syrjälä (Direct)

5.08%

5.08%

Acme Investments SPF Sarl (Indirect)

9.02%

9.02%

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

Luxembourg

Date of completion

10.05.2021

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLKZGMKZGZGMZM
Date   Source Headline
22nd Jun 20262:00 pmMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
17th Jun 20262:30 pmMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
17th Jun 20267:00 amMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
15th Jun 20264:00 pmMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
11th Jun 20263:05 pmMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
11th Jun 20263:00 pmMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Registration of Treasury Shares
10th Jun 20265:45 pmMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
8th Jun 20265:30 pmMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
5th Jun 202611:50 amMFNFaron Pharmaceuticals: Faron Pharmaceuticals Receives Decision from Nasdaq Helsinki Disciplinary Committee
4th Jun 20261:00 pmMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
3rd Jun 202612:00 pmMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Registration of New Shares
3rd Jun 20267:00 amMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds
1st Jun 20261:00 pmMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
28th May 20262:00 pmMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
28th May 20261:35 pmMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Issue of Treasury Shares to the Company
28th May 20261:30 pmMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Special Rights attached to the First and Second Tranche of Bonds
18th May 20267:00 amMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
6th May 20266:00 amMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Termination of Liquidity Provision Service
5th May 20267:30 amMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
5th May 20266:00 amMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Directorate Appointment
4th May 202611:00 amMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Results of the Annual General Meeting
30th Apr 20266:00 amMFNFaron Pharmaceuticals: Faron Pharmaceuticals Ltd: Issuance of warrants
22nd Apr 202611:30 amMFNFaron Pharmaceuticals: FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
20th Apr 20267:15 amMFNFARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
20th Apr 20267:00 amMFNFARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
16th Apr 20263:00 pmMFNFARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
14th Apr 202612:15 pmMFNFaron Pharmaceuticals Ltd: Remaining offer shares registered with Finnish Trade Register
14th Apr 20267:45 amMFNFaron Pharmaceuticals Ltd: Registration of New Shares
13th Apr 202611:00 amMFNFaron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds
10th Apr 20261:30 pmMFNNOTICE OF FARON PHARMACEUTICALS LTD’S ANNUAL GENERAL MEETING
10th Apr 202612:55 pmMFNFaron Pharmaceuticals Ltd: New shares registered with Finnish Trade Register
9th Apr 20265:25 pmMFNFaron publishes final results of its EUR 40.1 million rights issue
8th Apr 20262:15 pmMFNInside Information: Faron publishes preliminary results of its successful rights issue
31st Mar 20266:00 amMFNFaron Pharmaceuticals Ltd: Director Dealing
30th Mar 20267:30 amRNSSuspension - Faron Pharmaceuticals Oy
26th Mar 20267:00 amMFNFaron Pharmaceuticals Ltd: Faron appoints new CTO to strengthen late-stage development activities
25th Mar 20268:00 amMFNFaron Pharmaceuticals Ltd: Director Dealing
24th Mar 20264:30 pmMFNFARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
19th Mar 20267:10 amMFNFaron Pharmaceuticals Ltd: Director Dealing
19th Mar 20267:05 amMFNFaron Pharmaceuticals Ltd: Director Dealing
19th Mar 20267:00 amMFNFaron Pharmaceuticals Ltd: Director Dealing
12th Mar 20262:30 pmRNSFARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
12th Mar 20262:30 pmMFNFARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
11th Mar 20266:20 pmRNSThe Finnish Financial Supervisory Authority has approved Faron's rights offering prospectus
11th Mar 20266:20 pmMFNThe Finnish Financial Supervisory Authority has approved Faron's rights offering prospectus
11th Mar 20268:00 amRNSFARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
10th Mar 20267:48 amRNSInside Information: Faron publishes the terms and conditions of a fully covered rights offering of approximately EUR 40 million and updates cash runway
10th Mar 20267:48 amMFNInside Information: Faron publishes the terms and conditions of a fully covered rights offering of approximately EUR 40 million and updates cash runway
9th Mar 20265:45 pmMFNUpdate to Faron's Financial Calendar and date of the Annual General Meeting in 2026
4th Mar 20264:45 pmMFNCorrection: Faron Pharmaceuticals Ltd's Annual Report 2025 published

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.